Introduction
We described previously a specific gene-expression profile associated with genetic susceptibility to lung tumorigenesis in the normal lung of mouse inbred strains (Gariboldi et al., 2003) . Strain-dependent differential expression profiles in the target normal tissues have also been reported in other rodent models of genetic susceptibility to tumorigenesis (Falvella et al., 2002; Fujiwara et al., 2003; Riggs et al., 2005) , suggesting that alteration of gene-expression profile in normal organs might represent a general phenomenon associated with genetic predisposition to tumorigenesis.
In humans, genetic predisposition to the risk of lung cancer also seems to play a role in both smokers (Sellers et al., 1994; Hoover, 2000) and nonsmokers (Wu et al., 2004) . Indeed, genetic linkage analysis of pedigrees with multiple lung cancers mapped a lung cancer susceptibility locus to a region of chromosome 6 (Bailey- Wilson et al., 2004) . A gene-expression profile that distinguishes individuals at higher genetic risk of lung cancer might permit the use of non-invasive methods for the estimation of individual risk, such as analysis in induced sputum of proteins related to the specific gene-expression profile. It might also be possible to identify new genetic targets associated with the risk of lung cancer and develop new strategies for the prevention and early diagnosis of lung cancer.
In the present study, we compared the gene-expression profiles of normal lung tissue from lung adenocarcinoma (ADCA) patients and from patients with lung metastases from other primary tumor sites. We found that variations in mRNA levels of 85 genes are associated with lung cancer status and smoking habit. Among these genes, the AZGP1 gene showed the closest association with disease status and was characterized further.
Results
RNA pools from normal lung tissue of nonsmoker or smoker lung ADCA patients and non-lung cancer controls were hybridized to the Human U133 2.0 plus GeneChip. Genes that were not expressed in any of the four samples were removed from the analysis, thus reducing the number of transcripts from 54 676 to 33 363. Among the 250 transcripts showing the highest coefficient of variation, we selected the first 88 probes with >4-fold maximum difference among the samples. The 88 probes identified 85 independent transcripts, since AZGP1, RP13-36C9.1 and AGTR2 transcript probes were present twice. In principal component analysis to determine the extent of relationship among the samples based on the 85-transcript expression pattern, the main component on the x axis distinguished ADCA (left) from control (right) samples, whereas the second main component separated the nonsmoker (top) from the smoker (bottom) samples (Figure 1 ).
Microarray results were validated by kinetically monitored, reverse transcriptase-initiated PCR (kRT-PCR) of 27 genes in the same RNA pool. Results of the two assays correlated significantly (r ¼ 0.28; P ¼ 0.003), indicating that microarray analysis detected real variations in the gene-expression levels (not shown).
Among the group of 85 genes, a preliminary statistical analysis of microarray data to identify genes whose expression levels are associated with the lung cancer or non-lung cancer status pointed to AZGP1, IGLJ3 and FLJ22965 (Po0.05) and to HSPD1, BC006216 and RAB12 (P-values between 0.05 and 0.1) ( Table 2) . IGLJ3 and BC006216 were excluded from further analyses since they did not identify any specific transcript. Expression levels of AZGP1, FLJ22965, HSPD1 and RAB12 genes were validated by kRT-PCR in the same RNA pool used for microarray hybridization. FLJ22965, HSPD1 and RAB12 transcripts showed no significant association with disease status, whereas the AZGP1 transcript confirmed the microarray association and was analysed in all individual samples constituting the four RNA pools plus 49 additional specimens (Table 1) . kRT-PCR was carried out using TaqMan gene-expression assay normalized against hydroxymethylbilane synthase (HMBS), and relative quantity was calculated using a mix of equal amounts of the four RNA pools as a calibration sample.
To test variability and reproducibility of the kRT-PCR assay, analysis of AZGP1 was carried out twice in 12 lung ADCA patients and in 15 controls; results of the two independent experiments were highly correlated (r ¼ 0.95, Po0.0001).
AZGP1 expression levels were highly variable in the normal lung tissue of the analysed individuals, with relative quantity values ranging from 0.02 to 24.1 (mean7s.e. ¼ 1.670.3). No statistical association was observed between AZGP1 mRNA levels and sex, smoker status, age at diagnosis or clinical stage (stage I versus higher stages). However, a significant association was found between disease status and AZGP1 mRNA levels (P ¼ 0.01), with ADCA patients showing about twofold higher mean AZGP1 mRNA levels as compared to non-ADCA patients (Figure 2 ).
Immunohistochemical analysis revealed no detectable AZGP1 protein product in the normal lung, with weak cytoplasmic staining of only very few alveolar cells (Figure 3, top) . Most of the lung cancer samples were negative for AZGP1 protein expression and staining was clearly detected in the cytoplasm of only four samples, including a squamous cell carcinoma, an ADCA ( Figure 3 , bottom left), a bronchoalveolar carcinoma (Figure 3 , bottom right) and a mucoepidermoid carcinoma. Another squamous cell carcinoma and another ADCA also showed positive staining in a few cells.
By western blotting analysis, AZGP1 protein expression was apparent in normal lung tissue from either ADCA or non-lung cancer patients (Figure 4) .
Discussion
In the present study, we asked whether the geneexpression profile of human normal lung tissue might represent a potential signature of the individual genetic risk for lung cancer development. We compared normal lung tissue excised during lobectomy to remove lung cancer (cases) or lung metastasis of a non-lung cancer Figure 1 Principal component analysis of the correlation matrix of gene-expression levels in normal human lungs. Analysis included 85 genes whose expression levels showed the highest coefficient of variation in four RNA pools from lung ADCA or non-lung cancer patients (smokers or nonsmokers). The first factorial axis, which accounts for 38% of the total gene-expression phenotype variance, contrasts samples with gene expression correlated to lung cancer risk (left, lung ADCA patients; right, control subjects). The second factorial axis (36% of the variance) contrasts samples whose different gene expression is correlated with smoker status (top, nonsmokers; bottom, smokers). ADCA, adenocarcinoma. (Dragani, 2003) . While the genetic heterogeneity of the human population and the heterogeneity of exposure to environmental factors may modulate gene expression in the lung and limit the sensitivity of our analysis, we analysed separately smoker and nonsmoker subjects to reduce the confounding effect of the smoking habit. Notwithstanding these limitations, our study provides at least preliminary evidence supporting the hypothesis that genetic predisposition to lung cancer is accompanied by alteration of gene expression already apparent in the normal lung tissue.
Our use of pooled RNA to analyse four groups of specimens constituted by smoker or nonsmoker lung ADCA or non-lung cancer subjects is a cost-effective approach and allows for an overall picture of the differences among RNA pools (Kendziorski et al., 2005) .
The expression profile of 85 independent transcripts in the normal lung tissue was able to distinguish lung ADCA from non-lung cancer patients (Figure 1) . However, kRT-PCR analysis did not detect significant differences between cases and controls in gene-expression levels except for AZGP1. Most likely, the changes in expression of individual transcripts are of relatively small magnitude, although the 85 transcripts collectively may provide a signature of individual genetic predisposition to lung cancer.
The transcript of the AZGP1 gene, encoding a soluble 41-kDa protein (zinc-a2-glycoprotein, ZAG), was among the transcripts showing a statistical association with lung ADCA status. Independent kRT-PCR analysis in a series of 55 cases and 53 controls indicated B2-fold higher AZGP1 mRNA levels in normal lung of ADCA patients as compared to the corresponding tissue from non-lung cancer patients (Figure 2) , while immunohistochemical analysis of a tissue array did not detect AZGP1 expression in normal lung tissue, perhaps due to the lower sensitivity of tissue immunostaining as compared to kRT-PCR. AZGP1 protein was instead clearly detectable by western blot analysis, thus confirming that AZGP1 mRNA expression is associated with expression of its protein product in normal lung. The low sensitivity of tissue immunostaining as compared to western blot analysis may perhaps be associated with low local concentration of AZGP1 protein in tissue compartments, as opposed to relatively high protein concentration in electrophoretic bands. In addition, we detected AZGP1 protein expression in some lung cancer specimens of different histotype. AZGP1 expression was reported previously to be a predictor of prostate cancer prognosis, with decreased mRNA or protein levels associated with a higher risk of recurrence, metastatic progression or death (Lapointe Henshall et al., 2006) . At present, no data are available on the potential role of AZGP1 in lung cancer onset and/or progression. There is evidence that AZGP1 is present in most body fluids and in the secretory epithelial cells of many human tissues (Tada et al., 1991) . AZGP1 is an adipokine that may be involved in the local regulation of adipose tissue function by stimulating lipid degradation in adipocytes; the gene is markedly upregulated in mice with cancer cachexia (Bing et al., 2004) .
Comparison of our present microarray hybridization data in humans with the data obtained previously on mouse normal lungs (Gariboldi et al., 2003) identified only one gene, MCL1, with an expression profile shared by both species. However, kRT-PCR did not reveal significant differences between cases and controls, since MCL1 mRNA levels differed in this respect in nonsmokers but not in smokers ( Table 2) . The low concordance rate may rest in species differences, but also in differences in exposure between mouse strains (no exposure to any chemicals) and humans (smokers).
Consistent with previous reports (Spira et al., 2004; Harvey et al., 2007) , we found that the smoking habit is an important source of variability in the expression pattern of the normal lungs and that a specific geneexpression profile can distinguish ever-from neversmoker subjects (Figure 1) . The profile we identified in our samples did not overlap with profiles reported previously (Spira et al., 2004; Harvey et al., 2007) , but the discrepancy might reside in the use of different biological materials (bronchial cells recovered by bronchial brushing versus lung tissue specimens), different recruitment criteria and exposure to cigarette smoking, population genetic differences and different microarray platforms and methods of analysis. Among the genes confirmed by kRT-PCR to be associated with tobacco smoke exposure were HAS1 (hyaluronan synthase), CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1) and AHRR (aryl-hydrocarbon receptor repressor). mRNA levels of HAS1 were lower in smokers than in nonsmokers, whereas mRNA levels of CYP1A1 and AHRR were higher in smokers. Higher CYP1A1 levels in smokers as compared to nonsmokers were also found in a previous study using bronchoalveolar lavage cells (Thum et al., 2006) . Interestingly, a genetic polymorphism of the CYP1A1 gene seems to modulate inducibility of this gene in lymphocytes and to be associated with risk of lung ADCA (Crofts et al., 1994; Larsen et al., 2006) .
Although our preliminary study awaits confirmation in independent and larger series, our results suggest that a specific gene-expression profile of normal lung tissue can distinguish lung ADCA from non-lung cancer 1-3) or non-lung cancer subjects (lanes 4-6). ADCA, adenocarcinoma; ZAG, zinca2-glycoprotein.
patients. These findings support the hypothesis that genetic predisposition plays a role in lung ADCA risk through alteration of the gene-expression pattern in the normal tissue, as observed in animal models. These results might represent a basis for the development of tools to estimate individual risk for lung cancer, thus leading to improved lung cancer prevention and early diagnostic strategies.
Materials and methods

Patients and samples
Patients who underwent lung lobectomy for lung cancer or lung metastasis of non-lung cancers were recruited (Table 1) . A small piece of apparently normal lung tissue, distant from the macroscopic lung cancer tissue, was excised from the lung lobe removed at surgery and stored in RNAlater solution (Ambion, Austin, TX, USA). Smoking status was assessed by clinical records and subjects were scored as ever or never smokers. Total RNA was obtained using the RNeasy MIDI Kit (Qiagen, Valencia, CA, USA). RNA pools were prepared from nonsmoker lung ADCA cases (n ¼ 6), nonsmoker non-lung cancer controls (n ¼ 16), smoker lung ADCA cases (n ¼ 18) and smoker non-lung cancer controls (n ¼ 8).
Array hybridization and quantitative RT-PCR Double-stranded complementary DNA (cDNA) was synthesized from 5 mg of total RNA using a double-stranded cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA) with a poly-dT primer incorporating a T7 promoter. The cDNA was purified with the Affymetrix sample cleanup module (Affymetrix, Santa Clara, CA, USA). Biotin-labeled complementary RNA was generated from the double-stranded cDNA template by in vitro transcription with T7 polymerase using a nucleotide mix containing biotinylated UTP (3 0 -amplification reagents for IVT labelling kit; Affymetrix). The biotinylated complementary RNA was purified using the Affymetrix sample cleanup module. For each sample, 20 mg of IVT product was digested with fragmentation buffer (Affymetrix) for 35 min at 94 1C to an average size of 35-200 bases, and 15 mg of each fragmented biotinylated complementary RNA, along with hybridization controls (Affymetrix), was hybridized to a Human U133 2.0 plus GeneChip for 16 h at 45 1C and 60 r.p.m. Arrays were washed and stained according to the standard Antibody Amplification for Eukaryotic Targets protocol (Affymetrix). The stained arrays were scanned at 532 nm using an Affymetrix GeneChip Scanner 3000.
For quantitative PCR (kRT-PCR), RNAs from pooled or individual samples were reverse-transcribed using the ThermoScript RT-PCR system (Invitrogen). Gene-specific PCR primers amplifying 100-150 bp fragments were designed for 23 transcripts using the Unigene mRNA sequences. kRT-PCR amplification mixtures contained 1 ml template cDNA, 12.5 ml 2 Â QuantiTect SYBRGreen PCR Master Mix (Qiagen), and 0.3 mM specific PCR primers in a final volume of 25 ml. Reactions were run in triplicate on an ABI GeneAmp 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). The HMBS gene (GenBank accession no. NM_000190) was amplified with primers 5 0 -AGGATGGG CAACTGTACCTG-3 0 and 5 0 -GCCTACCAACTGTGGGT CAT-3 0 as a housekeeping control for possible differences in cDNA amounts.
mRNA levels of AZGP1 (Hs00426651_m1), FLJ22965 (Hs00254412_m1), HSPD1 (Hs01866140_g1) and RAB12 (Hs01391604_m1) were quantitated by kRT-PCR using TaqMan Gene Expression Assays (Applied Biosystems). The realtime PCR amplification mixture contained cDNA template diluted in RNase-free water, 10 ml 2 Â TaqMan Universal PCR Master Mix No AmpErase UNG (Applied Biosystems) and 1 ml of 20Â TaqMan Gene Expression Assay Mix (Applied Biosystems), in a final volume of 20 ml. Reactions were run in duplicate on the 7900HT System (Applied Biosystems) for 40 cycles (95 1C for 15 s, 60 1C for 1 min) after enzyme activation (95 1C for 10 min). The HMBS gene (Hs00609297_m1) was used as a control for possible differences in cDNA amounts. Relative expression levels were calculated using the comparative C t method.
Immunohistochemistry and western blotting
Immunohistochemical analysis of the AZGP1 encoded ZAG was conducted on normal or cancer lung tissues from our Pathology Department and also on commercial tissue arrays consisting of either 59 resected lung cancer specimens (CC2 Array) or their corresponding normal lung tissue (CCN2 array) from Korean patients (SuperBioChips Lab, Seoul, Korea). Tissue slides were preincubated in ethylenediaminetetraacetic acid buffer (pH 8.0) at 95 1C in an autoclave for 30 min and mixed with anti-ZAG (1D4) mouse monoclonal antibody raised against the human full-length ZAG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), used at a concentration of 1:100. Immunoreactivity was revealed by incubating the tissue microarray sections with UltraVision LP Detection System HRP Polymer (LabVision Corp., Fremont, CA, USA). Expression was visualized using 3,3 0 -diaminobenzidine (DAB þ , DAKO Inc., Carpinteria, CA, USA) as substrate and counterstained with hematoxylin solution.
Normal lung tissue of ADCA and non-lung cancer subjects was homogenized in lysis buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.9), 1.5 mM MgCl 2 and 10 mM KCl) containing 1 mM dithiothreitol and Protease Inhibitor Cocktail diluted 1:100 (P8340, Sigma, St Louis, MO, USA). After incubation on ice for 5 min, 1% IGEPAL CA-630 and 0.1% sodium dodecyl sulphate were added. Equal amounts (120 mg) of protein extracts were resolved by 10% polyacrylamide gel and transferred onto Hybond-C super nitrocellulose membranes (Amersham, Buckinghamshire, UK). Membrane was incubated with anti-ZAG (1D4) mouse monoclonal antibody (1:200 dilution) (Santa Cruz Biotechnology Inc.). The ECL system (Amersham) was used for detection.
Statistical analysis
Principal component analysis was carried out on the correlation matrix of the gene-expression levels expressed as log 2 values. Differences in kRT-PCR values by sex, smoker status or disease status were analysed by the Kruskal-Wallis test. Correlations between microarray and kRT-PCR results, between independent kRT-PCR assays, between kRT-PCR values and age at cancer onset were assessed using Pearson's correlation coefficient, r. Statistical procedures were carried out with SPSS 10.1 (SPSS Inc., Chicago, IL, USA) software.
